|
|
News Breaks | | | | January 3, 2013 | | 07:38 EDT |  | ZLCS | Zalicus initiates the second of two Phase 2a studies with Z160
Zalicus has initiated the second of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the potential treatment of chronic neuropathic pain. Z160 has demonstrated efficacy in several animal models of neuropathic pain, and clinical trials in over 200 subjects have established Z160 as a safe and well tolerated drug candidate. The second Phase 2a study with Z160 is enrolling subjects with Postherpetic Neuralgia, a chronic neuropathic pain state resulting from an outbreak of the herpes zoster virus, otherwise known as shingles. The 6-week, double-blind, multi-center, randomized, placebo-controlled study is expected to enroll approximately 140 subjects and will be conducted in approximately 35 centers throughout the United States. Top line data is expected to be available late in the second half of 2013. | |
|
News For ZLCS From The Last 14 Days Check below for free stories on ZLCS the last two weeks. |
|
|
| June 19, 2013 | | 16:03 EDT | | ZLCS | Zalicus publishes data on selective estrogen receptor modulators
 Subscribe for More Information | |
|
|
|
|
|
|
